• Products
• ProSavin^®
• RetinoStat^®
• StarGen™
• UshStat™
• EncorStat™
• MoNuDin^®
• TroVax^®
• Targeted Antibody Therapy
• Hi-8^® MEL
• MetXia^®
• EndoAngio-GT

MoNuDin^®

MoNuDin is a gene-based treatment for motor neuron disease. This progressive, usually fatal, neurodegenerative disease is caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement. MoNuDin uses the Company's LentiVector system to deliver a neuroprotective gene, vascular endothelial growth factor (VEGF), to prevent further degeneration of the motor neurons and potentially restore motor function.

Preclinical development Preclinical results in an industry-standard model of the disease suggest that MoNuDin may be one of the most effective potential therapies in the field to date. Further preclinical studies are ongoing with support from the UK Motor Neurone Disease Association, the US ALS Therapy Development Institute and the US Muscular Dystrophy Association.

Market opportunity Amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, is the most prevalent type of motor neuron disease. In the USA, there are an estimated 30,000 patients with ALS and nearly 6,000 new cases are diagnosed annually (source: ALS Association).